Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Cytos Biotechnology Ltd Stories

2014-02-13 00:21:11

ZURICH, February 13, 2014 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2013 financial results. Full year consolidated financial figures 2013: Balance sheet Funds available for financing the Company's operations amount to CHF 40.00 million as per December 31, 2013, and include cash and cash equivalents, financial assets and trade and other receivables. This is CHF 11.35 million higher than on December 31, 2012 (CHF 28.65...

2014-01-29 00:20:55

SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent...

2013-12-30 08:26:21

ZURICH, December 30, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Extraordinary Shareholders' Meeting. The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 29 shareholders. 15,609,347 shares or 51.14% of a total of 30,525,276 shares were represented. About...

2013-12-04 00:21:15

ZURICH, December 4, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that Dr. Yamo Deniz is proposed to join Cytos' Board of Directors. Dr. Deniz played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab (Xolair(R)) for the treatment of asthma in the US and the EU. His extensive experience in the clinical development of asthma...

2013-11-18 00:20:39

SCHLIEREN (ZURICH), Switzerland, November 18, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced the completion of a financing transaction that raised a total of CHF 24.3 million by selling 8.1 million shares at a price of CHF 3.00 per share. The rights offering was oversubscribed and share allocations included the use of authorized capital. International institutional investors as well as other shareholders have invested CHF...

2013-11-04 08:26:05

ZURICH, November 4, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Extraordinary Shareholders' Meeting the announced capital increase in particular. The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 28 shareholders. 12,673,384 shares or 56.55% of a total of 22,411,431 shares...

2013-10-31 04:21:22

ZURICH, October 31, 2013 /PRNewswire/ -- - Completion of patient enrolment in the ongoing Phase 2b clinical trial with CYT003 - Investor syndicate will pay Cytos CHF 6.625 million for achievement of this milestone - Share capital increase in form of a rights offering to be approved at an extraordinary shareholders' meeting on November 4, 2013 - CHF 9 million of the proposed capital increase is already firmly...

2013-10-21 04:21:04

Investor syndicate will pay Cytos CHF 6.625 million for achievement of this milestone under a convertible loan notes agreement signed in 2012 ZURICH, October 21, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003. This study investigates the effectiveness, safety and tolerability of CYT003 in patients with moderate to severe...

2013-10-17 16:24:56

SCHLIEREN, ZURICH, Switzerland, October 17, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) will host an Investor and Analyst R&D Day for institutional investors and research analysts on Wednesday, October 23, 2013 from 8:00 a.m. to 10:00 a.m. ET in New York City Christian Itin, Chairman and CEO as well as senior executives of Cytos will present on Cytos' lead program CYT003, which is in clinical development for the treatment of allergic asthma....

2013-09-09 00:21:15

Patients with baseline blood eosinophil counts above 0.1 cells/nL respond to treatment with CYT003 ZURICH, September 9, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced additional results of the phase 2a clinical trial with CYT003, a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. A post-hoc analysis of data published in the March issue of The Journal of Allergy and Clinical Immunology [1] are...